Dr. Bruetman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
160 E. Illinois Street
Chicago, IL 60611Phone+1 574-299-3838
Education & Training
Carnegie Mellon UniversityMaster in Medical Management(MMM), 2007 - 2008
Rush University Medical CenterFellowship, Hematology and Medical Oncology, 1987 - 1989- Advocate Health Care/Advocate Christ Medical CenterResidency, Internal Medicine, 1984 - 1987
University of Buenos AiresClass of 1983
Certifications & Licensure
IL State Medical License 1985 - 2026
IN State Medical License 2001 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
- Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer Start of enrollment: 2013 Feb 01
- Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Start of enrollment: 2013 Oct 22
- Join now to see all
Publications & Presentations
PubMed
- Differentiating agents in malignant disease.Daniel G. Bruetman, Jules E. Harris, Kenning M. Anderson
Medical and Pediatric Oncology. 1991-01-01 - Ductal carcinoma in situ of the breast.Bruetman D, Bloom K, Bines S
Medical and Pediatric Oncology. 1989-01-01
Press Mentions
- Efficacy of Margetuximab vs Trastuzumab in Patients with Pretreated ERBB2-Positive Advanced Breast CancerJanuary 22nd, 2021
74 Oncologists on the MoveOctober 11th, 2023
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
